AZD9291 free base · Synonyms: AZD-9291 | Mereletinib

Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor.

For research use only. Not for human or veterinary use.

Target EGFR

Research area Cancer

Purity >99% Stock Inquire

Data Sheet SDS COA

AZD9291 structure

CAS No.: 1421373-65-0

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 g	USD 220.00	BP-02469-25g	In stock	Get quote
100 g	USD 870.00	BP-02469-100g	In stock	Get quote
250 g	USD 1,750.00	—	In stock	Get quote
500 g	USD 2,810.00	—	In stock	Get quote
1 kg	USD 4,500.00	BP-02469-1kg	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer .

Biological activity

In Vitro Osimertinib (AZD9291) (0-10 μM; 72 hours) dramatically inhibits cell proliferation with IC50s of 41, 26, 41, and 31 nM, respectively. ? Osimertinib (0-10 μM; 72 hours) inhibits cell proliferation (Ba/F3 cells harboring a T790M mutation, exon 19del+T790M, or L858R+T790M) with IC50s of 6, 7, and 74 nM, respectively. ? Osimertinib (0-10 μM; 72 hours) inhibits Ba/F3 cells harboring EGFR exon 20 insertion mutations (IC50 ranging from 16 to 701 nM for A763_Y764insFQEA (FQEA), Y764_V765insHH (HH), A767_V769dupASV (ASV), and D770_N771insNPG (NPG) cells). ? Osimertinib shows high levels of phenotype potency in both sensitizing-mutant (mean IC50 of 8 nM in PC-9) and T790M (mean IC50s of 11 and 40 nM in H1975 and PC-9VanR respectively) EGFR cell lines. Osimertinib has much less activity towards wild-type EGFR (mean IC50s of 650 and 461 nM in Calu3 and H2073 respectively). ? Osimertinib (0.1 μM; 48 hours) induces apoptosis in Ba/F3 cells (apoptosis rates of 40.9% and 90% in EGFR exon 19del+T790M, EGFR L858R+T790M respectively) . In Vivo Osimertinib (0.1-25 mg/kg; p.o.; daily for 14 days) induces significant dose-dependent regression in both PC-9 (ex19del) and H1975 (L858R/T790M) tumor xenograft models.

Identifiers

SMILES: COC1=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C(NC(=O)C=C)C(=C1)N(C)CCN(C)C
InChIKey: DUYJMQONPNNFPI-UHFFFAOYSA-N

Specifications

MW (average): 499.6073
Formula: C₂₈H₃₃N₇O₂
CAS No.: 1421373-65-0
Physical state: Solid
Color: Light yellow to brown
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -20°C, 1 year;

Solubility

Soluble in DMSO

Documents

References

[1].Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.

[2]. Hirano T, et al. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer. Mol Cancer Ther. 2018 Apr;17(4):740-750.

Same target

Search EGFR

Same research area

Search Cancer